Cencora (COR) Stock Forecast & Price Target

$242.24 +1.26 (+0.52%)

(As of 12:05 PM ET)

Cencora - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
3

Buy
8

Based on 11 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 3 have given a hold rating, and 8 have given a buy rating for COR.

Consensus Price Target

$271.20
11.96% Upside

According to the 11 analysts' twelve-month price targets for Cencora, the average price target is $271.20. The highest price target for COR is $292.00, while the lowest price target for COR is $224.00. The average price target represents a forecasted upside of 11.96% from the current price of $242.24.

COR Analyst Ratings Over Time

Type	Current Forecast 11/21/23 to 11/20/24	1 Month Ago 10/22/23 to 10/21/24	3 Months Ago 8/23/23 to 8/22/24	1 Year Ago 11/21/22 to 11/21/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	9 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$271.20	$259.44	$258.63	$196.08
Forecasted Upside	11.96% Upside	9.68% Upside	7.50% Upside	-1.37% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Discover 2025’s Top Stock Pick 📈 (Ad)

As a seasoned trader, you understand the importance of identifying high-potential opportunities before they become mainstream. We’ve conducted in-depth analysis to pinpoint the #1 stock opportunity set to dominate in 2025 and beyond. Our exclusive report provides the strategic insights and advanced metrics that experienced investors like you need to stay ahead of the market.

[Get My Free Report]

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cencora Stock vs. The Competition

Type	Cencora	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	11.96% Upside	27,916.52% Upside	10.45% Upside
News Sentiment Rating	Positive News See Recent COR News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$287.00 ➝ $292.00	+17.29%
11/7/2024	UBS Group 4 of 5 stars		Boost Target	Buy ➝ Buy	$275.00 ➝ $285.00	+14.68%
11/7/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$263.00 ➝ $290.00	+18.18%
11/7/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$250.00 ➝ $285.00	+16.15%
10/7/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$277.00 ➝ $275.00	+25.03%
9/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Neutral	$275.00 ➝ $245.00	+4.46%
Discover 2025’s Top Stock Pick 📈 (Ad) As a seasoned trader, you understand the importance of identifying high-potential opportunities before they become mainstream. We’ve conducted in-depth analysis to pinpoint the #1 stock opportunity set to dominate in 2025 and beyond. Our exclusive report provides the strategic insights and advanced metrics that experienced investors like you need to stay ahead of the market. [Get My Free Report]
8/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$280.00 ➝ $287.00	+20.03%
8/1/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$236.00 ➝ $249.00	+3.96%
4/30/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$265.00 ➝ $280.00	+16.87%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/5/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$192.00 ➝ $224.00	-4.63%
8/7/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$205.00 ➝ $215.00	+15.07%
8/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$176.00 ➝ $190.00	-1.69%
5/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/3/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$174.00 ➝ $182.00	+8.81%
1/12/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$170.00 ➝ $190.00	+14.88%
11/22/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$175.00 ➝ $182.00	+13.54%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:31 PM ET.

Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 6, 2024. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

Cencora's stock price has been showing positive momentum, trading up to $228.11 on the latest trading day, indicating potential growth.
Major institutional investors like Vanguard Group Inc. and Price T Rowe Associates Inc. have recently added significant stakes in Cencora, reflecting confidence in the company's future prospects.
Analysts have given Cencora a consensus rating of "Moderate Buy" with an average price target of $256.67, suggesting room for stock price appreciation.
The company has a strong market capitalization of $45.50 billion, indicating stability and potential for long-term growth.
Cencora's current ratio of 0.89 and quick ratio of 0.55 show healthy liquidity levels, reducing the risk of financial distress.

Cencora
Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

Insiders, including Walgreens Boots Alliance, Inc., have been selling significant amounts of Cencora stock, which could signal lack of confidence in the company's future performance.
Cencora's debt-to-equity ratio of 3.93 is relatively high, indicating higher financial leverage and potential risks in case of economic downturns.
While some analysts have given positive ratings, others have downgraded Cencora's stock, suggesting mixed opinions on the company's outlook.
The company's P/E ratio of 24.96 and P/E/G ratio of 1.55 may indicate that the stock is currently overvalued compared to its growth prospects.
Cencora's 1 year high of $247.66 and 1 year low of $178.21 show volatility in the stock price, which could lead to uncertainty for investors.

COR Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $271.20, with a high forecast of $292.00 and a low forecast of $224.00.
: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" COR shares.
: According to analysts, Cencora's stock has a predicted upside of 11.96% based on their 12-month stock forecasts.
: Cencora has been rated by research analysts at Bank of America, Barclays, Evercore ISI, Leerink Partners, Robert W. Baird, and UBS Group in the past 90 days.
: Analysts like Cencora less than other "medical" companies. The consensus rating score for Cencora is 2.73 while the average consensus rating score for "medical" companies is 2.80. Learn more on how COR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Discover 2025’s Top Stock Pick 📈 (Ad)

[Get My Free Report]

This page (NYSE:COR) was last updated on 11/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cencora (COR) Stock Forecast & Price Target